Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Congenital bleeding disorders. Rational treatment options

S V Seremetis1, L M Aledort

  • 1Division of Hematology, Mount Sinai Hospital, New York, New York.

Drugs
|April 1, 1993
PubMed
Summary

Effective treatments exist for inherited bleeding disorders like hemophilia A and B, and von Willebrand disease. Current options offer comparable efficacy and safety, with ongoing research for inhibitor management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Editorial Foreword.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Chairman's Introduction.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Chairman's Synthesis and closing remarks.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Liver failure and mortality in HIV-positive haemophiliacs: FOURTEEN-YEAR EXPERIENCE AND LITERATURE REVIEW.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Modern treatment of haemophilia: choice of products for the treatment of haemophilia A and B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Area of Science:

  • Hematology
  • Pharmacology
  • Medical Science

Background:

  • Inherited bleeding disorders encompass hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and von Willebrand's disease.
  • Current treatment strategies involve factor replacement therapies, desmopressin, and management of complications like inhibitors.
  • Assessing safety, efficacy, and cost is crucial for selecting optimal treatment choices.

Purpose of the Study:

  • To review available, rational, and effective treatment options for common inherited bleeding disorders.
  • To evaluate the safety, efficacy, and cost-effectiveness of current therapies.
  • To identify areas for further research and development in bleeding disorder management.

Main Methods:

  • Literature review and assessment of existing clinical data on treatments for hemophilia A, hemophilia B, and von Willebrand's disease.
  • Analysis of safety profiles, efficacy outcomes, and cost considerations for various therapeutic products.
  • Examination of ongoing clinical trials for novel treatments, particularly for inhibitor management.

Main Results:

  • Currently available factor VIII and IX products for hemophilia A and B show comparable efficacy and viral safety, with high-purity products recommended for HIV-positive patients.
  • Desmopressin is effective for mild hemophilia A and most von Willebrand's disease cases.
  • Fresh frozen plasma is standard for factor XI deficiency, with alternatives under investigation. Treatment for inhibitors remains limited, with new agents in clinical trials.

Conclusions:

  • Rational and effective treatment choices are available for common inherited bleeding disorders based on safety, efficacy, and cost.
  • Further clarification is needed on the utility of factor IX concentrates in various clinical settings.
  • Active research is underway to improve the treatment of inhibitors, including the evaluation of recombinant factor VIIa, Xa, and tissue factor.

Related Experiment Videos